Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944972 | 0.80 | CA1 (0.47) | POLBTSHRSMN1; SMN2PKMLMNA | |
| SCHEMBL1615851 | 0.80 | CA1 (0.47) | MAPTMEN1MAPK1KMT2APOLB | |
| SCHEMBL2255243 | 0.80 | TDP1 (0.47) | RAB9AMAPTMEN1KMT2APOLB | |
| SCHEMBL29877642 | 0.80 | TDP1 (0.47) | RAB9AMAPTMEN1KMT2APOLB | |
| SCHEMBL29550577 | 0.80 | CA1 (0.47) | MAPTMEN1MAPK1KMT2APOLB | |
| SCHEMBL2961818 | 0.79 | SLC6A3 (0.38) | RAB9AMAPTMEN1MAPK1KMT2A | |
| SCHEMBL29381019 | 0.78 | CA1 (0.35) | RAB9AMAPTKDM4ETSHR | |
| SCHEMBL14152742 | 0.78 | CFTR (0.45) | MAPK1POLBKDM4ELMNA | |
| SCHEMBL29662636 | 0.78 | CFTR (0.45) | MAPK1POLBKDM4ELMNA | |
| SCHEMBL18132250 | 0.77 | BCL2L1 (0.38) | MEN1KMT2AKDM4ECXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-4508047-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-119255988-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2023198140-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-108003161-B | Neurotrophic factor tyrosine kinase receptor inhibitors | 正大天晴药业集团股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-2566859-B1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO LTD (KR) | 2016-12-21 | — | — | EP | disclosed |
| US-9096571-B2 | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2013-08-15 | — | — | US | disclosed |
| EP-2566859-A2 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Sk Chemicals Co., Ltd. (KR) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011139107-A2 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO.,LTD. (KR) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | HSD11B1, HSD11B2, G6PC1 | NPC1 849/4885RAB9A 4258/4885MAPT 3437/4885 |
| US-20250250269-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, IAPP | NPC1 828/4885RAB9A 789/4885MAPT 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.